Three cases of hemodiafiltration for the treatment of CAR-T related grade 3 - 4 cytokine release syndrome after ineffective treatment with IL-6 receptor inhibitors
10.3760/cma.j.issn.0253-2727.2022.06.009
- VernacularTitle:血液透析滤过处理CAR-T治疗后IL-6受体抑制剂治疗无效的3~4级细胞因子释放综合征3例
- Author:
Shiyu CHEN
1
;
Weihong CHEN
;
Xiaochun WAN
;
Xin DU
;
Changru LUO
;
Xiaoqing LI
;
Xiaohan ZHANG
Author Information
1. 深圳大学第一附属医院/深圳市第二人民医院血液内科，深圳 518035
- Keywords:
Hemodiafiltration;
Chimeric antigen receptor T cells;
Cytokine release syndrome;
IL-6 receptor inhibitor
- From:
Chinese Journal of Hematology
2022;43(6):494-498
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the efficacy and safety of hemodiafiltration (HDF) in treating CAR-T related grade 3-4 cytokine release syndrome after ineffective treatment with IL-6 receptor inhibitors.Methods:Between July 2015 and July 2021, retrospective analysis of hemodiafiltration for the treatment of 3 patients, including 2 cases of acute B-lymphoblastic leukemia and 1 case of diffuse large B-cell lymphoma, with grade 3-4 CRS after CAR-T cell therapy and ineffective treatment with IL-6 receptor inhibitor was carried out.Results:The patient's clinical symptoms, including body temperature, blood pressure, and blood oxygen, were relieved within 12 hours of all treatments, and the cytokines (IL-6, IL-10, TNF-α, INF-γ) and C-reactive protein (CRP) levels decreased significantly. No adverse side effects were observed during the follow-up period of 3 months.Conclusion:HDF can be a safe and feasible method to treat CAR-T related grade 3- 4 CRS after ineffective treatment with IL-6 receptor inhibitors.
